New Hope for Long-Term Survival in Late-Stage Patients: Overview of Five Major Targeted Drugs and Clinical Trials for Non-Small Cell Lung Cancer
EGFR In the Chinese patient population, EGFR is the most common driver gene mutation type in non-small cell lung cancer and is also one of the gene types with relatively good efficacy. However, even for this type of non-small cell lung cancer, there are still some “blind spots” in targeted therapy, such as certain difficult-to-treat … Read more